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Background
In 1872, Moritz Kaposi first described “an idiopathic multiple 
pigmented sarcoma of the skin,” now identified as Kaposi’s 
sarcoma (KS).1 While multiple forms of KS exist, over 95% of the 
cases diagnosed in the US since 1981 are of the AIDS associated 
variety.2 Kaposi originally described KS as skin lesions that can 
progress to visceral involvement. However, in a small number 
of cases, KS can appear in the viscera without skin involvement. 
These alternate presentations of KS are difficult to diagnose; 
therefore, it is critical to recognize them when considering 
differential diagnoses, particularly in patients with HIV. 
Case Presentation 
An 18-year-old African American male with a history of HIV 
presented with progressive worsening of diffuse and painful 
lymphadenopathy fore five weeks prior to admission. The 
patient was diagnosed with HIV in 2010 and due to insurance 
issues, was never treated with highly active antiretroviral therapy 
(HAART). His last CD4 count (approximately two weeks prior 
to admission) was 411 and he had no history of opportunistic 
infections. He first noticed swelling in his neck, under his 
armpits and in his groin five weeks prior, which had become 
progressively more painful. The patient denied fevers, chills or 
weight loss, but did report significant night sweats and episodes 
of hemoptysis with clots. He denied shortness of breath or chest 
pain. He also denied recent travel, history of incarceration, 
homelessness or exposure to active tuberculosis infection. 
On admission, the patient’s physical exam revealed numerous 
palpable, mobile and tender lymph nodes in the cervical, 
axillary and inguinal regions bilaterally. There was no overlying 
erythema and no skin lesions noted elsewhere. His lungs were 
clear to auscultation bilaterally. The remainder of his physical 
exam was within normal limits. His labs upon admission were 
notable for a hemoglobin of 9.4 and a platelet count of 9,000. 
The remainder of his labs were within normal limits. A chest 
x-ray demonstrated no consolidation or infiltrates. 
Hospital Course
The differential diagnosis for the HIV patient presenting with 
diffuse lymphadenopathy includes lymphoma, mycobacterium 
avium intracellular infection, tuberculosis with extra-
pulmonary involvement, fungal infection, Castleman’s disease, 
Kaposi’s Sarcoma, leukemia, infectious mononucleosis 
secondary to EBV or CMV, Bartonella infection (cat scratch 
disease), toxoplasmosis and secondary syphilis. Malignancy 
is a significant concern with the co-existing anemia and 
thrombocytopenia. He underwent a CT of the chest (Figure 1), 
abdomen and pelvis (Figures 2 and 3). Given his complaints of 
hemoptysis, the patient was placed on respiratory isolation and 
TB was ruled out by sputum acid fast bacilli stain and culture. 
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Figure 1. CT of the chest with IV contrast demonstrates ground 
glass opacity in the right upper lobe and bulky enhancing 
adenopathy in the bilateral axilla.
Figure 2. CT of the abdomen with IV contrast shows bulky 
enhancing intra- abdominal and para-aortic lymph nodes. 
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Rapid plasma reagin and monospot tests were also negative and 
repeat CD4 count was 194. The history, laboratory results and 
radiological findings required excisional lymph node biopsy for 
definitive diagnosis, but this was limited by the patient’s severe 
thrombocytopenia. Hematology was consulted and determined 
the thrombocytopenia likely represented HIV associated ITP, 
for which he was treated with IVIG and started on HAART. 
He was started on romiplostim to stimulate platelet production. 
On day 4 of his admission, the patient underwent a left inguinal 
lymph node excisional biopsy. Pathology was consistent 
with KS (Figures 4-7). It was assumed that his hemoptysis 
represented pulmonary involvement, although this could not 
be confirmed by bronchoscopy in the setting of thrombocy-
topenia. Although first line treatment for HIV-associated KS 
is HAART, the patient’s extensive and symptomatic disease 
required additional therapy. He received radiation for his bulky 
cervical adenopathy; however, he developed stridor during 
treatment and was intubated for airway maintenance. His ICU 
course was complicated by ventilator acquired pneumonia and 
he required a tracheostomy for continued airway maintenance. 
He was eventually weaned from the ventilator and started on 
liposomal doxorubicin on the general floor. After a nearly two 
month hospitalization, he was deemed stable for discharge 
home with a plan to continue HAART, weekly romiplostim, 
and chemotherapy as an outpatient. 
The patient was seen for follow up three weeks after discharge. 
His hemoptysis had resolved and his lymphadenopathy had 
decreased in size and was less painful. He continued to receive 
doxorubicin every other week and he required romiplostim 
for persistent thrombocytopenia. He no longer required 
supplemental oxygen and ENT planned to decannulate his 
tracheostomy.
Discussion
The Hungarian dermatologist Moritz Kaposi first described 
classic KS in 1872, as a rare, slow growing cutaneous tumor 
that mainly affects 50 to 70-year-old Jewish Mediterranean and 
Eastern European males. Since then, other varieties have been 
described including the African or endemic, and the immuno-
suppressed forms.3 In 1981, a fulminant and disseminated form 
of the disease appeared alongside HIV/AIDS. In fact, early in 
the epidemic, 48% of AIDS patients in the US presented with 
KS.2 KS typically begins with cutaneous lesions, which are 
usually dark patches, papules, plaques or nodules. Diagnosis 
requires biopsy with histopathology illustrating a multicentric 
angioproliferative spindle cell tumor that stains positive for the 
endothelial markers CD31 and CD34. Positive stain for HHV-8 
is also necessary but not sufficient for diagnosis, as the virus 
is also associated with multicentric Castlemans disease and 
primary effusion lymphoma in HIV patients. 
Although the vast majority of patients with KS present with skin 
lesions, the disease can involve the viscera, most commonly the 
oral mucosa, lung, liver, spleen, lymph nodes and the GI tract. 
Patients in later stages of disease can also experience fevers, 
weight loss and night sweats. Visceral involvement usually 
progresses from cutaneous disease, but in a small number of 
cases, it can be the primary site of involvement. This is seen 
Figure 4. Low power H&E stain of excised left inguinal lymph 
node demonstrates distortion of the normal lymph node 
architecture.
Figure 3. CT of the abdomen and pelvis demonstrates bilateral 
bulky enhancing inguinal lymph nodes.
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in KS cases involving the lymph nodes. Direct cutaneous 
invasion into nodes does not appear to worsen prognosis, but 
KS presenting solely with generalized lymphadenopathy is 
recognized as a disease more common in children and young 
adults that is associated with a worse prognosis.4
Regardless of the stage of KS, first line treatment is HAART. 
This has been shown in several trials, including one in which 
80% of patients naive to HAART with cutaneous disease showed 
regression with HAART alone.5 The utility of HAART extends 
to prevention as well, as demonstrated by the sharp decrease in 
AIDS and KS incidence with anti-retroviral therapy introduction 
in the 1990s. In fact, the incidence of KS decreased from 30/1000 
patient-years prior to 1995 to 0.03/1000 patient-years in 2001.2
Other modalities of treatment include radiation therapy and 
cytotoxic drugs. Radiation therapy for local disease can be an 
excellent option, with some series reporting 68-90% resolution 
of lesions, although the response in the epidemic form is 
less durable than in other forms of KS.6,7 Patients with more 
disseminated disease can be treated with systemic chemotherapy. 
Liposomal doxorubicin has been reported to have significantly 
higher response rates and possibly fewer side effects than other 
regimens including doxorubincin, bleomycin and vincristine.8,9 
Based on these studies, liposomal doxorubicin is now considered 
first-line treatment for advanced KS. Paclitaxel has also shown 
promising results and is considered second-line therapy.9
Conclusion
As KS is a heterogeneous disease, it must always be considered 
in the workup of patients with HIV/AIDS. As demonstrated by 
our case, patients can present with normal CD4 counts, lack 
skin lesions, and present with symptoms secondary to visceral 
involvement, including adenopathy, hemoptysis, gastroin-
testinal bleeding, and systemic symptoms. While KS is rarely 
a cause of death, it is not curable and can be disabling. Current 
management options are often able to symptomatically alleviate 
and improve quality of life.
References
1. Kaposi M. Idiopathic Multiple Pigmented Sarcoma of the Skin. CA Cancer J Clin 
32: 342-347
2. Selik RM, Starcher ET, Curran JW: Opportunistic diseases reported in AIDS 
patients: frequencies, associations, and trends. AIDS. 1(3):175-82, 1987
3. Antman K, Chang Y. Kaposi’s Sarcoma. New England Journal of Medicine 2000; 
342:1027-1038. 
4. Dutz, W. and Stout, A. P. (1960). Kaposi’s sarcoma in infants and children. 
Cancer(Philadelphia), 13,684-694.
5. Krown SE. Highly active antiretroviral therapy in AIDS-associated Kaposi’s 
sarcoma: implications for the design of therapeutic trials in patients with 
advanced, symptomatic Kaposi’s sarcoma. J Clin Oncol. 2004 Feb 1;22(3):399-402.
6. Berson AM, Quivey JM, Jarris JW, Wara WM. Radiation therapy for 
AIDS-related Kaposi’s Sarcoma. Int J Radiat Oncol Biol Phys. 1990 
Sep;19(3):569-75.
7. Cooper JS, Steinfeld AD, Lerch I. Intentions and outcomes in the radiothera-
peutic management of epidemic Kaposi’s sarcoma. Int J Radiat Oncol Biol Phys. 
1991 Mar;20(3):419-22.
8. Stewart S, Jablonowski H, Goebel FD, et al. Randomized comparative trial 
of pegylated liposomal doxorubicin versus bleomycin and vincristine in the 
treatment of AIDS-related Kaposi’s sarcoma. J Clin Oncol 1998;16:683-691.
9. Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin 
versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related 
Kaposi’s sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 
1998;16:2445-2451.
10. Gill PS, Tulpule A, Espina BM, et al. Paclitaxel is safe and effective in the treatment 
of advanced AIDS-related Kaposi’s Sarcoma. J Clin Oncol 1999; 17:1876-1883.
Figure 5. High power H&E stain of excised 
left inguinal lymph node with infiltration by 
angioproliferative spindle cells
Figure 6. Low power CD34 positive 
stain of excised left inguinal lymph node. 
Positive stain for CD 34 indicates vascular 
endothelium. Normal lymphatics do not 
stain positive for CD34.
Figure 7. HHV8 positive nuclear stain of 
excised left inguinal lymph node. Positive 
HHV8 stain is necessary for the diagnosis of 
Kaposi Sarcoma
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